Pierre Geborek

Treatment with tumor necrosis factor blockers is associated with a lower incidence of first cardiovascular events in patients with rheumatoid arthritis.

L. Jacobsson, Carl Turesson, Anders Gülfe et al. · PubMed · 2005 · 533 citations

Medicine, Internal Medicine, Pharmacotherapy +14

Risk and case characteristics of tuberculosis in rheumatoid arthritis associated with tumor necrosis factor antagonists in Sweden

Johan Askling, C. Michael Fored, Lena Brandt et al. · Arthritis & Rheumatism · 2005 · 415 citations

Medicine, Infectious Diseases, Internal Medicine +14

Individualized monitoring of drug bioavailability and immunogenicity in rheumatoid arthritis patients treated with the tumor necrosis factor α inhibitor infliximab

Klaus Bendtzen, Pierre Geborek, Morten Svenson et al. · Arthritis & Rheumatism · 2006 · 379 citations

Medicine, Immunology, Pharmacology +17

Cancer risk in patients with rheumatoid arthritis treated with anti–tumor necrosis factor α therapies: Does the risk change with the time since start of treatment?

Johan Askling, Ronald van Vollenhoven, Fredrik Granath et al. · Arthritis & Rheumatism · 2009 · 240 citations

Medicine, Clinical Sciences, Internal Medicine +15

Conventional combination treatment versus biological treatment in methotrexate-refractory early rheumatoid arthritis: 2 year follow-up of the randomised, non-blinded, parallel-group Swefot trial

Ronald van Vollenhoven, Pierre Geborek, Kristina Forslind et al. · The Lancet · 2012 · 225 citations

Medicine, Clinical Sciences, Pharmacotherapy +9